Recombinant Human CD69 Protein

重组人CD69蛋白 | 重组人细胞粘附分子69蛋白

activation inducer molecule (AIM/CD69) | Activation inducer molecule | AIM | BL-AC/P26 | CD69 antigen (p60, early T-cell activation antigen) | CD69 antigen | CD69 molecule | CD69 | CLEC2CC-type lectin domain family 2 member C | C-type lectin domain family

rp181591-10μg

10μg

无动物源

≥95%(SDS-PAGE)

Early activation antigen CD69, also known as activation inducer molecule (AIM), is a single-pass type II membrane protein. Recently, cDNA clones encoding human and mouse CD69 were isolated and showed CD69 to be a member of the C-type lectin superfamily. It is one of the earliest cell surface antigens expressed by T cells following activation. Once expressed, CD69 acts as a costimulatory molecule for T cell activation and proliferation. In addition to mature T cells, CD69 is inducibly expressed by immature thymocytes, B cells, natural killer (NK) cells, monocytes, neutrophils and eosinophils, and is constitutively expressed by mature thymocytes and platelets. CD69 is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. The structure, chromosomal localization, expression and function of CD69 suggest that it is likely a pleiotropic immune regulator , potentially important in the activation and differentiation of a wide variety of hematopoietic cells. This membrane molecule transiently expresses on activated lymphocytes, and its selective expression in inflammatory infiltrates suggests that it plays a role in the pathogenesis of inflammatory diseases. CD69 plays a crucial role in the pathogenesis of allergen-induced eosinophilic airway inflammation and hyperresponsiveness and that CD69 could be a possible therapeutic target for asthmatic patients. Post-translational: Constitutive Ser/Thr phosphorylation in both mature thymocytes and activated T-lymphocytes.

Testing in progress

重组表达

17.0 kDa

N-9His

22.7 & 28.0 kDa, under reducing conditions; 21.8 & 26.0 & 39.4 kDa, under non-reducing conditions.

HEK293 Accession #: Q07108 | HEK293

<1.0 EU/μg

人(Human)

64-199 aa

HHHHHHHHHGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYK

Yes

Yes